Introduction
The global human population is predicted to rise to 11.2 billion by 2100, according to the United Nations, leading to increasing demand for animal-derived food production. Over recent years the welfare of farmed livestock species has been placed at the forefront for consumers and farmers (Fernandes et al. Reference Fernandes, Hemsworth, Coleman and Tilbrook2021; Vigors et al. Reference Vigors, Ewing and Lawrence2021). The pursuit of optimum animal welfare and the desire for livestock animals to ‘experience positive lives’ (Vigors et al. Reference Vigors, Ewing and Lawrence2021) has driven researchers and producers to seek to improve the welfare of farmed animals (Alonso et al. Reference Alonso, González-Montaña and Lomillos2020; Lucas et al. Reference Lucas, Hemsworth and Hemsworth2023). In the UK there are over 10,000 pig holdings as of 2021, with 60% of UK sows farmed indoors (Woods Reference Woods2019; AHDB 2024).
Vaccination is commonly used as a preventative strategy against disease and pigs are typically vaccinated during their production lifecycle (Gebhardt et al. Reference Gebhardt, Tokach, Dritz, DeRouchey, Woodworth, Goodband and Henry2020; Temple et al. Reference Temple, Jiménez, Escribano, Martín-Valls, Díaz and Manteca2020). Delivery of vaccines is commonly achieved via intramuscular (IM) injection (Có-Rives et al. Reference Có-Rives, AY-A and Moore2023), however, concerns exist over the use and reuse of needles to deliver these vaccines. Best-practice would see needles changed between use on each individual animal however the reuse of needles is commonplace within the industry (AHDB 2019). A recent study by Owen et al. (Reference Owen, Blackie and Gibson2022) revealed that 81% of farmers surveyed reuse the needle and there was variation in the frequency of needle change. In addition, the study demonstrated that needles become damaged after 12 uses. Therefore, a welfare concern of the IM method is the pain caused by the procedure, especially when needles are reused. Another concern is the potential of infection being spread between pigs. For example, porcine reproductive and respiratory syndrome virus (PPRSV) has been shown to spread to susceptible pigs via contaminated needles (Pileri & Mateu Reference Pileri and Mateu2016). Thirdly, a public health issue is that broken needles can be left in the pig carcases leading to food health and safety issues (Imeah et al. Reference Imeah, Penz, Rana and Trask2020). Whilst alternatives for IM vaccinations exist, such as intranasal or oral vaccines, there are limited options that are commercially available (Temple et al. Reference Temple, Jiménez, Escribano, Martín-Valls, Díaz and Manteca2020).
Another alternate method is intradermal (ID) vaccination, which can be achieved using needle-free devices (NFDs) and has been reported to reduce the negative effects imposed by needle syringes (Có-Rives et al. Reference Có-Rives, AY-A and Moore2023). Multiple vaccines are now available to be delivered using NFDs, and studies have confirmed humoral and cell-mediated immune responses (Cho et al. Reference Cho, Ahn, Oh, Suh and Chae2022; Madapong et al. Reference Madapong, Saeng-chuto, Tantituvanont and Nilubol2021; Yang et al. Reference Yang, Oh, Mago, Iwakuma and Chae2020). Porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae are two challenging porcine pathogens for which vaccinations are highly effective (Yang et al. Reference Yang, Oh, Mago, Iwakuma and Chae2020) and MHYOSPHERE® PCV ID (Hipra laboratories, Spain) is the first vaccine that can be administered intradermally to protect against both pathogens (Puig et al. Reference Puig, Bernal, Sabaté, Ballarà, Montané, Nodar, Angelats and Jordà2022).
A systematic review conducted by Có-Rives et al. (Reference Có-Rives, AY-A and Moore2023) identified that 35% of skin-based inoculations use NFDs (jet injectors). Whereas 17.9 and 10.7% used needles/syringes or microneedles, respectively, and 18.6% of studies did not specify the device used which may increase the percentage using a needle-based approach (Có-Rives et al. Reference Có-Rives, AY-A and Moore2023). This indicates a recent upsurge in the usage of ID NFDs, with commercial devices namely the IntraDermal Application of Liquids (IDAL) (Merck, Germany) and the Hipradermic (HIPRA, Spain) available.
There are multiple advantages of NFDs as removing needles from the equation can avoid issues previously highlighted. In one study, Salman et al. (Reference Salman, Lin, Suntisukwattana, Watcharavongtip, Jermsutjarit, Tantituvanont and Nilubol2023) demonstrated minimising disease transmission specifically, African swine fever virus was unable to be transmitted by using the IDAL instead of IM needles. Positive welfare benefits for pigs have also been discovered, for instance, studies have reported NFD causing a reduction in pain and aversive behaviour (Temple et al. Reference Temple, Escribano, Jiménez, Mainau, Cerón and Manteca2017, Reference Temple, Jiménez, Escribano, Martín-Valls, Díaz and Manteca2020; Scollo et al. Reference Scollo, Minervini, Galli, Cevidalli, Bortoletto, Romano and Gottardo2020; Dalmau et al. Reference Dalmau, Sánchez-Matamoros, Molina, Xercavins, Varvaró-Porter, Muñoz, Moles, Baulida, Fàbrega, Velarde, Pallisera, Puigredon and Contreras-Jodar2021).
With a growing interest in NFD and new commercially available devices entering the market, it is essential that claims about improving welfare are substantiated. This study, therefore, aims to explore the welfare (as measured through pig behaviour) benefits of a previously unreported ID NFD on a commercial UK pig unit.
Materials and methods
Ethical statement
The experimental protocols described in the study were approved (2022-1621) by the ethical review panel at ARU Writtle, UK.
Animal, housing and experimental procedure
A total of 179 piglets (crossbreed with genetic make-up of 50% Large White, 25% Landrace, and 25% Pietrain) on a commercial farm in Essex, UK were included in this study and either vaccinated at four weeks of age via an ID NFD or by an IM method. The study was repeated over two trials: Trial 1 included 91 piglets (46 vaccinated via ID NFD procedure and 45 by IM) in six pens (three for each treatment); and Trial 2 included 88 piglets (44 ID NFD and 44 IM) which used four pens (two for each treatment). Litters were weaned at approximately 28 days of age and separated into pens (2.5 × 3.6 m; length × width), in groups of 18–20 piglets balanced for weight. Each pen had plastic slatted floors, water was provided from nipple feeders and pigs were fed ad libitum. Enrichment items such as a rope and plastic toys were provided in each pen.
The pigs were split into two treatments: (i) Pigs vaccinated against Porcine Circovirus type 2 (PCV2) with a 1 mL intramuscular vaccination with Ingelvac CircoFLEX® (Boehringer Ingelheim; Germany) (IM) a water-based vaccine expressing ORF2 antigen of PCV2; and (ii) Pigs vaccinated against PCV2 and Mycoplasma hyopneumoniae with 0.2 mL Mhyosphere® (Hipra Laboratories, Spain). An oil-based vaccine that contains inactivated recombinant Mycoplasma hyopneumoniae and the capsid protein of PCV2 delivered via an ID NFD, specifically the Hipradermic® 3.0, a battery-powered device.
There were a total of ten pens, with five pens per treatment. Vaccinations were completed in the morning by trained persons and all pigs were handled in the same manner to administer the vaccines. In brief, one person’s role was to hold the piglet for the ID group whilst another person used the NFD, and IM piglets were handled and vaccinated by the same person. The vaccines for both treatments were administered in the neck region. This study did not include a non-vaccinated control group since our objective was to observe the behaviour exhibited by piglets vaccinated using two different routes.
Behavioural measures
The general activity of the piglets was measured using instantaneous scan sampling at 1 and 24 h post-vaccination (after the last pig was vaccinated), using an ethogram adapted from the Dalmau et al (2021) study (Table 1). Behaviours were recorded every 6th min during a period of 180 min for each pen and a total of 600 observations were taken. Each pen was recorded using an H.265 4MP Eyeball PoE infrared dome camera (Genie, WIP4BV5) installed by Clearview (UK). The videos were recorded onto a 3 TB hard drive-equipped H.265 eight-channel network video recorder (Genie, WNVR185) (Clearview 2023). All recorded videos per pen were watched and behaviours recorded by two trained observers. To avoid bias, the videos were split between the two observers and balanced across the two treatments. In addition, the incidence of piglet vocalisation during vaccination was recorded on an individual level at point of vaccination prior to pen allocation on a yes or no basis. Observers were not blinded in this study.
Table 1. The ethogram used for scan sampling piglet behaviour adapted from Dalmau et al. ( Reference Dalmau, Sánchez-Matamoros, Molina, Xercavins, Varvaró-Porter, Muñoz, Moles, Baulida, Fàbrega, Velarde, Pallisera, Puigredon and Contreras-Jodar2021 )
Physical measurements
To assess the impact of the vaccines on growth, piglets were weighed on the day of vaccination and one week post-vaccination (at approximately five weeks of age). The incidence of papules was also assessed one week post-vaccination (papule formation denotes successful delivery of vaccine into the dermis layer; Bik et al. Reference Bik, Van Doorn, Boeijink, Wennekers, Meesters, Bloemen, Haedersdal and Wolkerstorfer2022).
Statistical analysis
Statistical analysis was completed using GenStat 22nd edition (VSNi). Trial did not have an effect on observations, therefore the five pens of piglets per treatment was considered the replicate within the analysis. The effect of vaccine type and time after vaccination (including interactions between these) on behaviours was analysed via a two-way ANOVA. Counts of observations for each behaviour were summed for each observation period, then the incidence of behaviour as a percent of the total possible observations was used in analysis. The following behaviours were combined prior to statistical analysis due to low instances of observation: ‘Side-lying’ combined observed behaviours of ‘lying right’ and ‘lying left’; ‘Moving’ combined ‘locomotion’, ‘manipulating fixtures’, ‘playing’ and ‘escape attempt’; and ‘Standing or sitting’ combined ‘standing’ and ‘sitting’. Chi-squared tests comparing vaccine type were carried out on the counts of whether piglets vocalised at the point of vaccination. We used t-tests to compare the averages of piglet weights at vaccination and one week post-vaccination between the two vaccination types.
Results
Behavioural observations
The piglets showed no significant difference in behaviours observed between the two vaccine delivery methods (Table 2). Piglets were observed spending more time drinking and feeding at 24 h compared to 1 h post-vaccination (P < 0.001).
Table 2. The percentage of piglet behaviours recorded at two scan sampling timepoints (1 h and 24 h) post-vaccination with either an Intradermal (ID) or Intramuscular (IM) vaccine. Standard error of difference (SED) was calculated between the vaccine type and time to show effect size.
1 SED = Standard Error of Difference.
*** indicates significance at P < 0.001.
There was no significant difference in the proportion of piglets that vocalised during IM compared to ID vaccination (51% and 43%, respectively; P = 0.329; Figure 1).
Figure 1. The proportion (%) of piglets (n = 179) that vocalised (‘Yes’ [light grey]) compared to those that did not (‘No’ [dark grey]) at the time of vaccination in each treatment group. ID: Intradermal; IM: Intramuscular.
Physical measurements
At the start of the trials all piglets were weighed pre-vaccination and were at a similar average weight between ID: 7.71 (± 1.64) kg and IM: 7.39 (± 1.79) kg. However, ID piglets were significantly heavier one week post-vaccination compared to IM piglets (8.49 [± 1.79] kg and 7.58 [± 1.79] kg, respectively; P < 0.001; Figure 2). Papules were noted after the vaccine (< 1 h) was given in the ID piglets however there was no evidence of papules after seven days.
Figure 2. Mean (± SD) piglet (n = 179) weights (kg) at pre-vaccination (left) at four weeks of age and (right) post-vaccination at five weeks of age for each treatment group (ID: intradermal [dark grey], IM: intramuscular [light grey]). A t-test was performed and showed non-significance (NS) and significance indicated at P < 0.001.
Discussion
This study revealed minimal differences in piglet behaviour and welfare between the two different routes of vaccination. It follows on from similar studies on piglets that were in different settings (either experimental or commercial) (Temple et al. Reference Temple, Escribano, Jiménez, Mainau, Cerón and Manteca2017, Reference Temple, Jiménez, Escribano, Martín-Valls, Díaz and Manteca2020; Dalmau et al. 2021; Puig et al. Reference Puig, Bernal, Sabaté, Ballarà, Montané, Nodar, Angelats and Jordà2022; Salman et al. Reference Salman, Lin, Suntisukwattana, Watcharavongtip, Jermsutjarit, Tantituvanont and Nilubol2023) with this study using pigs in a UK commercial setting.
The piglets’ behavioural response was assessed through scan sampling and vocalisations as per previous work (Dalmau et al. 2021). Vocalisation at the time of vaccination has been measured as an indicator of pain. A similar percentage of pigs (55%) did not vocalise at the point of vaccination in Scollo et al.’s (Reference Scollo, Minervini, Galli, Cevidalli, Bortoletto, Romano and Gottardo2020) study using the IDAL to deliver Porcilis® (M.hyopneumoniae; MSD Animal Health, US) and Porcilis® (PCV2; MSD Animal Health). While Temple et al.’s (Reference Temple, Jiménez, Escribano, Martín-Valls, Díaz and Manteca2020) study only focused on high-pitched vocalisations as a sign of stress and noted 25% more piglets vocalised in the IM group compared to the control or ID. Analysing the pitch and length of vocalisation could provide additional evidence to support the welfare benefits of ID vaccinations and should be considered in the future.
Regarding the scan sampling of piglets, no behaviour showed a significant treatment effect across the two time-points which was in accordance with the findings of Dalmau et.al (2021). However, a minimal effect of treatment on different lying positions was reported which differs from previous findings. Dalmau et al. (2021) used UNISTRAIN® (Hipra, Spain) to vaccinate for porcine reproductive and respiratory syndrome (PRRS) as well as environmental differences which may explain the differences in responses observed. Previous research has indicated that vaccines have different reactogenicity profiles based on the inflammatory response which can be influenced by the adjuvant type, antigen dose and physicochemical properties (Hervé et al. Reference Hervé, Laupèze, Del Giudice, Didierlaurent and Tavares Da Silva2019). The significant increase in piglets eating and drinking at 24 h compared to 1 h post-weaning was seen within both treatments and likely not an effect of the vaccine but instead a result of acclimatisation to the new environment. No adverse behavioural effects were demonstrated in piglets vaccinated using the ID route which is a positive outcome suggesting no drop in welfare compared to the industry-wide, currently accepted IM method. This can be used to promote the uptake of NFDs and encourage future research into other possible benefits.
Papule formation, as noted earlier, is a local response from ID vaccination and indicates successful delivery of the vaccine into the dermis layer (Bik et al. Reference Bik, Van Doorn, Boeijink, Wennekers, Meesters, Bloemen, Haedersdal and Wolkerstorfer2022). The literature has reported visible papules from 21 to 28 days post-vaccination. However, here, papules resolved by day 7 post-vaccination and are in agreement with previous reports that this is not an adverse effect and does not influence any behaviour. Piglets in the ID treatment group one week post-vaccination were heavier compared to the IM group (P < 0.001). This is in accordance with previous findings where the avoidance of invasive and stressful procedures, such as invasive surgical procedures, has been associated with weight gain (Morgan et al. Reference Morgan, Itin-Shwartz, Koren, Meyer, Matas, Younis, Novak, Weizmann, Rapaic, Abu Ahmad, Klement and Raz2019). Also, Puig et al. (Reference Puig, Bernal, Sabaté, Ballarà, Montané, Nodar, Angelats and Jordà2022) reported that replacing IM vaccines with the Mhyosphere® delivered ID resulted in a higher growth performance in the first weeks post-weaning. In this study, weight gain could be considered both a welfare and a production benefit.
Animal welfare implications
This study revealed the ID NFD to not cause any negative impacts on the piglets’ welfare and, while not empirically evidenced, it could be presumed the lack of injection improved the piglets’ vaccination experience, thereby improving their welfare. This supports the literature claiming that ID NFDs offer an alternative that benefits animal welfare (Temple et al. Reference Temple, Escribano, Jiménez, Mainau, Cerón and Manteca2017, Reference Temple, Jiménez, Escribano, Martín-Valls, Díaz and Manteca2020; Scollo et al. Reference Scollo, Minervini, Galli, Cevidalli, Bortoletto, Romano and Gottardo2020; Dalmau et al. 2021; Có-Rives et al. Reference Có-Rives, AY-A and Moore2023). Future studies should aim to evaluate the potential benefits of the device, such as the reduction in labour and promotion of health to both piglets and farmers. To promote high quality animal welfare, ID NFDs such as the Hipradermic 3.0 should be further investigated in commercial farm settings and promoted for future use.
Acknowledgements
The authors are thankful to HIPRA for their support, especially Jonathan McKechnie and provision of the Hipradermic 3.0 device. Funding was received from Research England.
Competing interest
None.
Open access
